KROS · Keros Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Jasbir Seehra Chief Executive Officer | ▲ Buy | Option Exercise | 440,708 Shares held | 4/2/2026 | View profile |
| Lachey Jennifer Chief Scientific Officer | ▼ Sell | Open Market | 95,100 Shares held | 7/15/2022 | View profile |
| Rovaldi Christopher Chief Operating Officer | ▲ Buy | Grant | 60,000 Shares held | 2/18/2025 | View profile |
| Tanini Annita Corp. Controller & VP, Finance | ▼ Sell | Open Market | 45,144 Shares held | 8/18/2026 | View profile |
| ORBIMED ADVISORS LLC Director | ▼ Sell | Other | 45,057 Shares held | 11/21/2025 | View profile |
| Carl L. Gordon Director | ▼ Sell | Other | 45,057 Shares held | 11/21/2025 | View profile |
| CHYUNG YUNG H. Chief Medical Officer | ▲ Buy | Grant | 44,000 Shares held | 2/18/2025 | View profile |
| Keith Regnante Chief Financial Officer | ▼ Sell | Open Market | 39,261 Shares held | 2/18/2026 | View profile |
| Esther Cho SVP, General Counsel | ▼ Sell | Open Market | 35,770 Shares held | 8/18/2026 | View profile |
| Lorena Raquel Lerner Chief Science Officer | ▼ Sell | Open Market | 27,559 Shares held | 8/18/2026 | View profile |
| Jean Jacques Bienaime Chief Executive Officer | ▲ Buy | Open Market | 19,592 Shares held | 8/17/2026 | View profile |
| Anne Prener | ▲ Buy | Grant | 13,786 Shares held | 7/1/2026 | View profile |
| Mary Ann Gray Director | ▲ Buy | Grant | 12,392 Shares held | 6/3/2026 | View profile |
| Charles W. Newton Chief Financial Officer | ▼ Sell | Open Market | 12,114 Shares held | 8/18/2026 | View profile |
| Julius Knowles Director | ▼ Sell | Open Market | 10,958 Shares held | 6/4/2026 | View profile |
| Nima Farzan | ▼ Sell | Open Market | 9,767 Shares held | 6/4/2026 | View profile |
| Alpna Seth | ▼ Sell | Open Market | 9,767 Shares held | 6/4/2026 | View profile |
| Tomer Kariv Director | ▲ Buy | Grant | 5,250 Shares held | 6/4/2025 | View profile |
| Ran Nussbaum Director | ▲ Buy | Grant | 5,250 Shares held | 6/4/2025 | View profile |
| ADAR1 Capital Management, LLC 10% Owner | ▼ Sell | Open Market | 0 Shares held | 10/15/2025 | View profile |
| Pontifax Management 4 G.P. (2015) Ltd. 10% Owner | ▼ Sell | Open Market | 0 Shares held | 10/15/2025 | View profile |
Transaction History
| Tanini Annita | ▼ Sell | Open Market | 1,224 | $13K | 8/18/2026 |
| Lorena Raquel Lerner | ▼ Sell | Open Market | 3,568 | $37K | 8/18/2026 |
| Esther Cho | ▼ Sell | Open Market | 4,485 | $46K | 8/18/2026 |
| Charles W. Newton | ▼ Sell | Open Market | 551 | $6K | 8/18/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 1,000 | $10K | 8/17/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 1,000 | $11K | 7/15/2026 |
| Anne Prener | ▲ Buy | Grant | 13,786 | $0 | 7/1/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 1,000 | $10K | 6/15/2026 |
| Charles W. Newton | ▼ Sell | Open Market | 550 | $6K | 6/11/2026 |
| Alpna Seth | ▼ Sell | Open Market | 2,625 | $28K | 6/4/2026 |
| Julius Knowles | ▼ Sell | Open Market | 2,625 | $28K | 6/4/2026 |
| Nima Farzan | ▼ Sell | Open Market | 2,625 | $28K | 6/4/2026 |
| Alpna Seth | ▲ Buy | Grant | 7,142 | $0 | 6/3/2026 |
| Nima Farzan | ▲ Buy | Grant | 7,142 | $0 | 6/3/2026 |
| Jean Jacques Bienaime | ▲ Buy | Grant | 7,142 | $0 | 6/3/2026 |
| Julius Knowles | ▲ Buy | Grant | 7,142 | $0 | 6/3/2026 |
| Mary Ann Gray | ▲ Buy | Grant | 7,142 | $0 | 6/3/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 1,000 | $11K | 5/15/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 1,000 | $12K | 4/15/2026 |
| Jasbir Seehra | ▲ Buy | Option Exercise | 55,000 | $17K | 4/2/2026 |
| Charles W. Newton | ▲ Buy | Grant | 13,215 | $0 | 3/9/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 2,000 | $22K | 3/9/2026 |
| Jasbir Seehra | ▼ Sell | Open Market | 7,015 | $113K | 2/19/2026 |
| Lorena Raquel Lerner | ▼ Sell | Open Market | 3,873 | $63K | 2/18/2026 |
| Esther Cho | ▼ Sell | Open Market | 4,745 | $78K | 2/18/2026 |
| Keith Regnante | ▼ Sell | Open Market | 4,739 | $77K | 2/18/2026 |
| ORBIMED ADVISORS LLC | ▼ Sell | Other | 140,057 | $2.5M | 11/21/2025 |
| ORBIMED ADVISORS LLC | ▼ Sell | Other | 74,465 | $1.3M | 11/21/2025 |
| Carl L. Gordon | ▼ Sell | Other | 140,057 | $2.5M | 11/21/2025 |
| Carl L. Gordon | ▼ Sell | Other | 74,465 | $1.3M | 11/21/2025 |
| Julius Knowles | ▼ Sell | Other | 191,527 | $3.4M | 11/21/2025 |
| Julius Knowles | ▼ Sell | Other | 130,494 | $2.3M | 11/21/2025 |
| Pontifax Management 4 G.P. (2015) Ltd. | ▼ Sell | Open Market | 2,284,612 | $40.6M | 10/15/2025 |
| Pontifax Management 4 G.P. (2015) Ltd. | ▼ Sell | Open Market | 1,121,045 | $19.9M | 10/15/2025 |
| Pontifax Management 4 G.P. (2015) Ltd. | ▼ Sell | Open Market | 1,226,412 | $21.8M | 10/15/2025 |
| Pontifax Management 4 G.P. (2015) Ltd. | ▼ Sell | Open Market | 155,262 | $2.8M | 10/15/2025 |
| ADAR1 Capital Management, LLC | ▼ Sell | Open Market | 4,391,237 | $77.9M | 10/15/2025 |
| ADAR1 Capital Management, LLC | ▼ Sell | Open Market | 254,669 | $4.5M | 10/15/2025 |
| ADAR1 Capital Management, LLC | ▼ Sell | Open Market | 743,358 | $13.2M | 10/15/2025 |
| Jasbir Seehra | ▲ Buy | Grant | 90,500 | $0 | 9/3/2025 |
| ADAR1 Capital Management, LLC | ▼ Sell | Other | 100 | $6K | 6/20/2025 |
| ADAR1 Capital Management, LLC | ▼ Sell | Other | 1,400 | $98K | 6/20/2025 |
| ADAR1 Capital Management, LLC | ▼ Sell | Other | 200 | $14K | 6/20/2025 |
| Ran Nussbaum | ▲ Buy | Grant | 5,250 | $0 | 6/4/2025 |
| Alpna Seth | ▲ Buy | Grant | 5,250 | $0 | 6/4/2025 |
| Julius Knowles | ▲ Buy | Grant | 5,250 | $0 | 6/4/2025 |
| Carl L. Gordon | ▲ Buy | Grant | 5,250 | $0 | 6/4/2025 |
| Tomer Kariv | ▲ Buy | Grant | 5,250 | $0 | 6/4/2025 |
| Nima Farzan | ▲ Buy | Grant | 5,250 | $0 | 6/4/2025 |
| Jean Jacques Bienaime | ▲ Buy | Grant | 5,250 | $0 | 6/4/2025 |
| Mary Ann Gray | ▲ Buy | Grant | 5,250 | $0 | 6/4/2025 |
| ADAR1 Capital Management, LLC | ▲ Buy | Open Market | 500,000 | $5.2M | 4/9/2025 |
| ADAR1 Capital Management, LLC | ▲ Buy | Open Market | 325,000 | $3.2M | 4/9/2025 |
| ADAR1 Capital Management, LLC | ▲ Buy | Open Market | 74,333 | $768K | 4/9/2025 |
| ADAR1 Capital Management, LLC | ▲ Buy | Open Market | 16,365 | $154K | 4/9/2025 |
| ADAR1 Capital Management, LLC | ▲ Buy | Open Market | 18,560 | $174K | 4/9/2025 |
| Jasbir Seehra | ▲ Buy | Option Exercise | 49,367 | $15K | 4/4/2025 |
| CHYUNG YUNG H. | ▲ Buy | Grant | 44,000 | $0 | 2/18/2025 |
| Keith Regnante | ▲ Buy | Grant | 44,000 | $0 | 2/18/2025 |
| Rovaldi Christopher | ▲ Buy | Grant | 60,000 | $0 | 2/18/2025 |
| Carl L. Gordon | ▼ Sell | Open Market | 29,400 | $1.3M | 8/13/2024 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 220,600 | $9.7M | 8/13/2024 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 29,400 | $1.3M | 8/13/2024 |
| Carl L. Gordon | ▼ Sell | Open Market | 220,600 | $9.7M | 8/13/2024 |
| Keith Regnante | ▲ Buy | Option Exercise | 40,000 | $640K | 11/4/2023 |
| Keith Regnante | ▼ Sell | Open Market | 40,000 | $1.8M | 11/4/2023 |
| Keith Regnante | ▲ Buy | Option Exercise | 20,000 | $320K | 6/9/2023 |
| Keith Regnante | ▼ Sell | Open Market | 15,993 | $720K | 6/9/2023 |
| Keith Regnante | ▼ Sell | Open Market | 1,428 | $66K | 6/9/2023 |
| Keith Regnante | ▼ Sell | Open Market | 2,579 | $122K | 6/9/2023 |
| Keith Regnante | ▲ Buy | Option Exercise | 20,000 | $320K | 6/8/2023 |
| Keith Regnante | ▼ Sell | Open Market | 17,301 | $825K | 6/8/2023 |
| Keith Regnante | ▼ Sell | Open Market | 2,699 | $131K | 6/8/2023 |
| Jasbir Seehra | ▲ Buy | Option Exercise | 4,000 | $2K | 4/8/2023 |
| Ran Nussbaum | ▼ Sell | Other | 1,914 | $0 | 11/29/2022 |
| Tomer Kariv | ▼ Sell | Other | 1,723 | $0 | 11/29/2022 |
| Tomer Kariv | ▼ Sell | Other | 1,914 | $0 | 11/29/2022 |
| Tomer Kariv | ▼ Sell | Other | 3,539 | $0 | 11/29/2022 |
| Pontifax Management 4 G.P. (2015) Ltd. | ▼ Sell | Other | 3,539 | $0 | 11/29/2022 |
| Pontifax Management 4 G.P. (2015) Ltd. | ▼ Sell | Other | 1,723 | $0 | 11/29/2022 |
| Pontifax Management 4 G.P. (2015) Ltd. | ▼ Sell | Other | 1,914 | $0 | 11/29/2022 |
| Ran Nussbaum | ▼ Sell | Other | 3,539 | $0 | 11/29/2022 |
| Ran Nussbaum | ▼ Sell | Other | 1,723 | $0 | 11/29/2022 |
| Lachey Jennifer | ▲ Buy | Option Exercise | 46,034 | $14K | 7/15/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 46,034 | $1.4M | 7/15/2022 |
| Lachey Jennifer | ▲ Buy | Option Exercise | 1,916 | $575 | 7/13/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 1,916 | $57K | 7/13/2022 |
| Lachey Jennifer | ▲ Buy | Option Exercise | 9,400 | $3K | 6/14/2022 |
| Jasbir Seehra | ▲ Buy | Option Exercise | 5,000 | $2K | 6/9/2022 |
| Lachey Jennifer | ▲ Buy | Option Exercise | 5,300 | $2K | 5/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 944 | $40K | 5/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 3,398 | $140K | 5/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 719 | $31K | 5/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 223 | $10K | 5/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 16 | $727 | 5/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 1,009 | $63K | 4/11/2022 |
| Lachey Jennifer | ▲ Buy | Option Exercise | 5,300 | $2K | 4/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 2,315 | $147K | 4/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 559 | $36K | 4/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 1,417 | $87K | 4/11/2022 |
| Rovaldi Christopher | ▲ Buy | Option Exercise | 1,728 | $28K | 4/6/2022 |
| Rovaldi Christopher | ▼ Sell | Open Market | 1,728 | $112K | 4/6/2022 |
| Lachey Jennifer | ▲ Buy | Option Exercise | 7,950 | $2K | 4/4/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 7,950 | $477K | 4/4/2022 |
| Rovaldi Christopher | ▲ Buy | Option Exercise | 864 | $14K | 4/1/2022 |
| Rovaldi Christopher | ▼ Sell | Open Market | 2 | $109 | 4/1/2022 |
| Rovaldi Christopher | ▼ Sell | Open Market | 104 | $6K | 4/1/2022 |
| Rovaldi Christopher | ▼ Sell | Open Market | 287 | $16K | 4/1/2022 |
| Rovaldi Christopher | ▼ Sell | Open Market | 366 | $21K | 4/1/2022 |
| Rovaldi Christopher | ▼ Sell | Open Market | 105 | $6K | 4/1/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 875 | $48K | 3/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 713 | $38K | 3/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 1,062 | $56K | 3/11/2022 |
| Lachey Jennifer | ▲ Buy | Option Exercise | 2,650 | $795 | 3/11/2022 |
| Lachey Jennifer | ▲ Buy | Option Exercise | 2,650 | $795 | 2/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 199 | $11K | 2/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 1,378 | $72K | 2/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 1,073 | $55K | 2/11/2022 |
| Lachey Jennifer | ▲ Buy | Option Exercise | 2,650 | $795 | 1/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 320 | $17K | 1/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 1,196 | $64K | 1/11/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 1,134 | $62K | 1/11/2022 |
| Lachey Jennifer | ▲ Buy | Option Exercise | 2,650 | $795 | 1/5/2022 |
| Lachey Jennifer | ▼ Sell | Open Market | 2,650 | $159K | 1/5/2022 |
| Julius Knowles | ▼ Sell | Open Market | 419 | $24K | 1/5/2022 |
| Julius Knowles | ▼ Sell | Open Market | 271 | $16K | 1/5/2022 |
| Julius Knowles | ▼ Sell | Open Market | 1,356 | $79K | 1/5/2022 |
| Julius Knowles | ▼ Sell | Open Market | 886 | $52K | 1/5/2022 |
| Julius Knowles | ▼ Sell | Open Market | 667 | $39K | 1/5/2022 |
| Julius Knowles | ▼ Sell | Open Market | 435 | $26K | 1/5/2022 |
| Julius Knowles | ▼ Sell | Open Market | 524 | $29K | 1/4/2022 |
| Julius Knowles | ▼ Sell | Open Market | 794 | $44K | 1/4/2022 |
| Julius Knowles | ▼ Sell | Open Market | 2,124 | $119K | 1/4/2022 |
| Julius Knowles | ▼ Sell | Open Market | 1,383 | $78K | 1/4/2022 |
| Julius Knowles | ▼ Sell | Open Market | 1,707 | $97K | 1/4/2022 |
| Julius Knowles | ▼ Sell | Open Market | 1,113 | $63K | 1/4/2022 |
| Julius Knowles | ▼ Sell | Open Market | 4,151 | $241K | 1/4/2022 |
| Julius Knowles | ▼ Sell | Open Market | 2,704 | $157K | 1/4/2022 |
| Julius Knowles | ▼ Sell | Open Market | 3,367 | $198K | 1/4/2022 |
| Julius Knowles | ▼ Sell | Open Market | 2,195 | $129K | 1/4/2022 |
| Julius Knowles | ▼ Sell | Open Market | 3,412 | $201K | 1/3/2022 |
| Julius Knowles | ▼ Sell | Open Market | 249 | $15K | 1/3/2022 |
| Julius Knowles | ▼ Sell | Open Market | 162 | $10K | 1/3/2022 |
| Julius Knowles | ▼ Sell | Open Market | 5,094 | $295K | 1/3/2022 |
| Julius Knowles | ▼ Sell | Open Market | 3,678 | $209K | 1/3/2022 |
| Julius Knowles | ▼ Sell | Open Market | 2,406 | $137K | 1/3/2022 |
| Julius Knowles | ▼ Sell | Open Market | 3,318 | $192K | 1/3/2022 |
| Julius Knowles | ▼ Sell | Open Market | 5,236 | $309K | 1/3/2022 |
| Lachey Jennifer | ▲ Buy | Option Exercise | 735 | $221 | 12/15/2021 |
| Lachey Jennifer | ▼ Sell | Open Market | 735 | $37K | 12/15/2021 |
| Lachey Jennifer | ▲ Buy | Option Exercise | 1,915 | $575 | 12/13/2021 |
| Lachey Jennifer | ▼ Sell | Open Market | 390 | $20K | 12/13/2021 |
| Lachey Jennifer | ▼ Sell | Open Market | 7 | $375 | 12/13/2021 |
| Lachey Jennifer | ▼ Sell | Open Market | 1,518 | $76K | 12/13/2021 |
| Julius Knowles | ▼ Sell | Open Market | 79 | $4K | 12/2/2021 |
| Julius Knowles | ▼ Sell | Open Market | 52 | $3K | 12/2/2021 |
| Julius Knowles | ▼ Sell | Open Market | 6,372 | $339K | 12/2/2021 |
| Julius Knowles | ▼ Sell | Open Market | 4,155 | $221K | 12/2/2021 |
| Julius Knowles | ▼ Sell | Open Market | 8,747 | $471K | 12/2/2021 |
| Julius Knowles | ▼ Sell | Open Market | 5,705 | $307K | 12/2/2021 |
| Julius Knowles | ▼ Sell | Open Market | 138 | $8K | 12/2/2021 |
| Julius Knowles | ▼ Sell | Open Market | 90 | $5K | 12/2/2021 |
| Julius Knowles | ▼ Sell | Open Market | 4,243 | $227K | 12/1/2021 |
| Julius Knowles | ▼ Sell | Open Market | 2,766 | $148K | 12/1/2021 |
| Julius Knowles | ▼ Sell | Open Market | 5,168 | $283K | 12/1/2021 |
| Julius Knowles | ▼ Sell | Open Market | 3,372 | $184K | 12/1/2021 |
| Julius Knowles | ▼ Sell | Open Market | 2,528 | $141K | 12/1/2021 |
| Julius Knowles | ▼ Sell | Open Market | 1,649 | $92K | 12/1/2021 |
| Julius Knowles | ▼ Sell | Open Market | 1,566 | $88K | 12/1/2021 |
| Julius Knowles | ▼ Sell | Open Market | 1,021 | $57K | 12/1/2021 |
| Lachey Jennifer | ▲ Buy | Option Exercise | 5,300 | $2K | 11/11/2021 |
| Lachey Jennifer | ▼ Sell | Open Market | 739 | $43K | 11/11/2021 |
| Lachey Jennifer | ▼ Sell | Open Market | 4,561 | $273K | 11/11/2021 |
| Lachey Jennifer | ▲ Buy | Option Exercise | 15,900 | $5K | 11/10/2021 |
| Lachey Jennifer | ▼ Sell | Open Market | 15,900 | $954K | 11/10/2021 |
| Lachey Jennifer | ▲ Buy | Option Exercise | 10,600 | $3K | 11/4/2021 |
| Lachey Jennifer | ▼ Sell | Open Market | 10,600 | $530K | 11/4/2021 |
| Julius Knowles | ▼ Sell | Open Market | 2,346 | $100K | 11/3/2021 |
| Julius Knowles | ▼ Sell | Open Market | 3,957 | $165K | 11/3/2021 |
| Julius Knowles | ▼ Sell | Open Market | 6,067 | $253K | 11/3/2021 |
| Julius Knowles | ▼ Sell | Open Market | 3,597 | $153K | 11/3/2021 |
| Julius Knowles | ▼ Sell | Open Market | 2,120 | $89K | 11/2/2021 |
| Julius Knowles | ▼ Sell | Open Market | 991 | $43K | 11/2/2021 |
| Julius Knowles | ▼ Sell | Open Market | 3,252 | $137K | 11/2/2021 |
| Julius Knowles | ▼ Sell | Open Market | 1,518 | $65K | 11/2/2021 |
| Julius Knowles | ▼ Sell | Open Market | 7,350 | $312K | 11/1/2021 |
| Julius Knowles | ▼ Sell | Open Market | 4,599 | $192K | 11/1/2021 |
| Julius Knowles | ▼ Sell | Open Market | 4,797 | $204K | 11/1/2021 |
| Julius Knowles | ▼ Sell | Open Market | 7,057 | $295K | 11/1/2021 |
| Julius Knowles | ▼ Sell | Open Market | 1,463 | $56K | 10/20/2021 |
| Julius Knowles | ▼ Sell | Open Market | 229 | $9K | 10/20/2021 |
| Julius Knowles | ▼ Sell | Open Market | 148 | $6K | 10/20/2021 |
| Julius Knowles | ▼ Sell | Open Market | 2,242 | $86K | 10/20/2021 |
| Julius Knowles | ▼ Sell | Open Market | 460 | $18K | 10/19/2021 |
| Julius Knowles | ▼ Sell | Open Market | 704 | $27K | 10/19/2021 |
| Julius Knowles | ▼ Sell | Open Market | 1,323 | $50K | 10/19/2021 |
| Julius Knowles | ▼ Sell | Open Market | 2,029 | $77K | 10/19/2021 |
| Julius Knowles | ▼ Sell | Open Market | 8,252 | $311K | 10/18/2021 |
| Julius Knowles | ▼ Sell | Open Market | 5,382 | $203K | 10/18/2021 |
| Julius Knowles | ▼ Sell | Open Market | 92 | $4K | 10/18/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial
Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial. Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.